Herantis Pharma Oyj (HRTIS) - Cash Flow Conversion Efficiency

Latest as of June 2025: -1.937x

Based on the latest financial reports, Herantis Pharma Oyj (HRTIS) has a cash flow conversion efficiency ratio of -1.937x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.39 Million ≈ $-3.96 Million USD) by net assets (€1.75 Million ≈ $2.04 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Herantis Pharma Oyj worth for the company's overall valuation and market capitalisation.

Herantis Pharma Oyj - Cash Flow Conversion Efficiency Trend (2012–2024)

This chart illustrates how Herantis Pharma Oyj's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Herantis Pharma Oyj Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Herantis Pharma Oyj ranked by their cash flow conversion efficiency. Explore Herantis Pharma Oyj earnings quality ratio to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
BlockchAIn Digital Infrastructure, Inc NYSE MKT:AIB	0.064x
Seondo Electric Co., Ltd. KO:007610	-0.100x
Histeel KO:071090	0.121x
Raphas Co. Ltd KQ:214260	0.031x
PASSUS S.A. ZY-1 F:71X	0.559x
Jembo Cable Company Tbk JK:JECC	-0.109x
HILONG HOLDING LTD HD-10 F:8HL	N/A
Samkee Automotive Co. Ltd KQ:122350	0.044x

Annual Cash Flow Conversion Efficiency for Herantis Pharma Oyj (2012–2024)

The table below shows the annual cash flow conversion efficiency of Herantis Pharma Oyj from 2012 to 2024. View today's stock price for Herantis Pharma Oyj for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	€-243.00K ≈ $-284.09K	€-6.54 Million ≈ $-7.65 Million	26.934x	+2845.91%
2023-12-31	€4.73 Million ≈ $5.53 Million	€-4.64 Million ≈ $-5.42 Million	-0.981x	-100.66%
2022-12-31	€-60.28K ≈ $-70.48K	€-8.94 Million ≈ $-10.46 Million	148.365x	+927.89%
2021-12-31	€554.30K ≈ $648.04K	€-9.93 Million ≈ $-11.61 Million	-17.921x	-1488.32%
2020-12-31	€7.59 Million ≈ $8.87 Million	€-8.56 Million ≈ $-10.01 Million	-1.128x	+64.95%
2019-12-31	€1.85 Million ≈ $2.16 Million	€-5.96 Million ≈ $-6.97 Million	-3.219x	-107.70%
2018-12-31	€-89.29K ≈ $-104.39K	€-3.73 Million ≈ $-4.36 Million	41.801x	+6678.70%
2017-12-31	€4.09 Million ≈ $4.78 Million	€-2.60 Million ≈ $-3.04 Million	-0.635x	+67.04%
2016-12-31	€1.57 Million ≈ $1.84 Million	€-3.04 Million ≈ $-3.55 Million	-1.928x	-56.32%
2015-12-31	€6.00 Million ≈ $7.01 Million	€-7.40 Million ≈ $-8.65 Million	-1.233x	-514.33%
2014-12-31	€21.72 Million ≈ $25.39 Million	€-4.36 Million ≈ $-5.10 Million	-0.201x	+89.26%
2013-12-31	€120.00K ≈ $140.29K	€-224.21K ≈ $-262.13K	-1.868x	-101.18%
2012-12-31	€-3.37K ≈ $-3.94K	€-533.42K ≈ $-623.62K	158.097x	--

About Herantis Pharma Oyj

HE:HRTIS Finland Biotechnology

Market Cap

$43.69 Million

€37.37 Million EUR

Market Cap Rank

#22500 Global

#112 in Finland

Share Price

€1.41

Change (1 day)

-1.40%

52-Week Range

€1.41 - €2.78

All Time High

€10.10